m+Medelevator.RU
← Поиск публикаций
Annals of medicine · 2026

Research progress of mesenchymal stem cells/stromal cells and their derivatives against cell senescence in the treatment of osteoarthritis.

СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Deng Daihua, Wu Yinlan, Wu Tong, Huang Deying, Liang Xiuping, Tan Chunyu, Li Yanhong, Liu Yi

Аннотация

BACKGROUND: Cellular senescence plays a critical role in the pathogenesis and progression of osteoarthritis (OA), contributing to articular cartilage degradation, chronic inflammation, and joint function impairment. Mesenchymal stem cells/stromal cells (MSCs) and their derivatives have emerged as potential targets for novel therapeutic strategies against cell senescence in OA, as they exert anti-aging effects in repairing damaged cartilage through multiple mechanisms-including regulating age-related signaling pathways, reducing the secretion of pro-inflammatory cytokines, and improving mitochondrial function.

DISCUSSION: In recent years, a growing body of in-depth studies has focused on various types of MSCsand their derivatives, revealing subtle differences in their anti-cell senescence pathways and therapeutic effects. This review summarizes the latest cutting-edge research, systematically exploring the multi-dimensional roles of these MSCs and their derivatives in ameliorating senescent cell-related pathology in OA, and highlighting their potential clinical application value.

CONCLUSIONS: Despite the promising anti-aging effects of MSCs and their derivatives in OA treatment, further molecular-level mechanistic studies and large-scale clinical trials are required to verify the efficacy and safety of therapies based on their anti-cell senescence properties. These efforts are expected to provide new breakthroughs in the clinical management of OA, offering more effective treatment options for patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты